Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).

Skoulidis F, Jabbour SK, Garon EB, Iyengar P, Scagliotti G, Ferrer L, Etchepare G, Gallinato O, Faure J, Bernard P, Colin T, Menu P, Lin Y, Cai L, Chaudhry AA, Remorino A, Stewart R, Luciani-Silverman L, Miller K, Dellamonica D, Faria J, Zhang Y

Open source

DOI: 10.1158/1078-0432.ccr-25-3729
Published: 2026 Jul 22
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-3729,
  title = {Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).},
  author = {Skoulidis F and Jabbour SK and Garon EB and Iyengar P and Scagliotti G and Ferrer L and Etchepare G and Gallinato O and Faure J and Bernard P and Colin T and Menu P and Lin Y and Cai L and Chaudhry AA and Remorino A and Stewart R and Luciani-Silverman L and Miller K and Dellamonica D and Faria J and Zhang Y},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-3729},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-3729}
}

RIS

TY  - JOUR
TI  - Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).
AU  - Skoulidis F
AU  - Jabbour SK
AU  - Garon EB
AU  - Iyengar P
AU  - Scagliotti G
AU  - Ferrer L
AU  - Etchepare G
AU  - Gallinato O
AU  - Faure J
AU  - Bernard P
AU  - Colin T
AU  - Menu P
AU  - Lin Y
AU  - Cai L
AU  - Chaudhry AA
AU  - Remorino A
AU  - Stewart R
AU  - Luciani-Silverman L
AU  - Miller K
AU  - Dellamonica D
AU  - Faria J
AU  - Zhang Y
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-3729
UR  - https://doi.org/10.1158/1078-0432.ccr-25-3729
ER  -

APA

F, S., SK, J., EB, G., P, I., G, S., L, F., G, E., O, G., J, F., P, B., T, C., P, M., Y, L., L, C., AA, C., A, R., R, S., L, L., K, M., D, D., J, F., & Y, Z. (2026). Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-3729

Source records

pubmed · retrieved 2026-09-27T06:24:07.289Z